Replies to post #486522 on NorthWest Biotherapeutics Inc (NWBO)

[JohnnyMacJohnJohn]

I don't think you can claim 5 QALYs when you only have a 12% approx. chance of 5 year survival. I could be wrong but that's how I see it.

[ATLnsider]

I agree CrashOverride.

[hoffmann6383]

great info crash.

[flipper44]

According to that document, it’s 150k the first year and 50k each year thereafter until individual supply runs out. That would be 350k total if a patient had enough supply to last five years. That would average 70k per year over five years (not 40k). With manual manufacturing. Monetary unit = pounds.

[biosectinvestor]

I believe the NHS has many good reasons to want this industry and company well situated in the UK. So I believe it will be covered. I do not claim that the price now will be the final price nor that they won’t have a reasonable justification for whatever that price will be.

I believe that the NHS likely believes that having the only company with this futuristic oncology treatment in the UK, creating jobs, is a big positive for the UK.

[flipper44]

You are incorrect when more doses are available and purchased.

According to the current Advent price sheet, with manual production:

If an individual patient has enough DCVax-l and received 10 doses (three years worth), it would cost 250k pounds total.

If a patient has enough DCVax-l and received 12 doses (four years), it would cost 300k pounds total.

If a patient has enough DCVax-l and received 14 doses (five years), it would cost 350k pounds total.

[EMHLondonUK]

Crash (Bio FYI), I largely agree with your maths.

You might even get a bit higher reimbursement if the SoC with DCVax allows the NHS to avoid some other interventions. Plus the low toxicity profile means there won’t be a meaningful adverse events ‘tax’ from NICE, either.